Back to state act
Description
On 1 October 2020, the Norwegian Medicines Agency introduced an export notification on apixaban and all types of immunoglobulins. Notably, a notification requirement immunoglobulins with the exception...
Sign in to see full description
Intervention Details
Intervention Type
Export licensing requirement
MAST Chapter
P: Export-related measures (incl. subsidies)
Implementation date
01 Oct 2020
Revocation date
03 Mar 2021
Implementation level
National
Affected flow
Outward
Announced as temporary
Yes
Eligible firms
all
Affected Trading Partners
Table
Affected Sectors
Sign in to access 1 sectors
Affected Products
Sign in to access 4 products
Threads
See all
This intervention is not part of any Thread yet.